The ASC4FIRST trial has shown asciminib, a novel BCR::ABL1 inhibitor, as a promising alternative to current tyrosine kinase inhibitors (TKIs) for chronic phase (CP) chronic myeloid leukaemia (CML).

Receive News24 Business writer-at-large Carol Paton's articles about the political economy, state-owned enterprises and energy sector.

the studio behind that country’s famous Godzilla movie monster — has unveiled a deal to acquire GKIDS, the North American indie producer and distributor. Financial terms of the agreement were ...

and onboards new distributors in extremities and trauma markets in Australia and the United Kingdom (UK) For the remainder of the second half of 2024, Kuros expects a similar seasonal sales pattern as ...